OBJECTIVE: ST-segment elevation acutemyocardial infarction(STEMI) in very young adults is uncommon. Many studies have focused on the cutoff of 45-50 years old to define young patients with STEMI leaving limited data on the group of very young patients aged less than 35 years old. We investigated the incidence of STEMI in different subgroups of young patients and focused on the characteristics, possible pathogenesis and outcomes in very young patients aged less than 35 years old. Continue reading →

IRVINE, Calif.--(BUSINESS WIRE)-- TherOx, a ZOLL Medical company, announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO2) Therapy at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium Sept. 25-29 at the Moscone Center in San Francisco. Presentations include an overview and case study of SSO2 Therapy the first and only FDA-approved new heart attack treatment beyond PCI to reduce infarct size and updated results of the IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study conducted to support FDA approval, granted in April 2019 Continue reading →

Self Regional Healthcare, a participant in the American Heart Association Mission: Lifeline Regional Reports, has received the Mission: Lifeline Regional STEMI Trailblazer Achievement Award as a part of the South Carolina Region. The award is presented for implementing specific quality improvement measures at a regional level as outlined by the Association for treating patients who suffer severe heart attacks. This is the first year the Association has recognized regional achievement as part of its awards program for quality patient care Every year, more than 250,000 people experience an ST elevation myocardial infarction (STEMI), the deadliest type of heart attack, caused by a blockage of blood flow to the heart that requires timely treatment. Continue reading →

WASHINGTON: As the cannabis industry continues to evolve, researchers are constantly uncovering positive aspects of the plant. A study by the University of Colorado suggests that cannabis can be used to increase the survivability of a heart attack Continue reading →

Myocardial infarction or heart attack is an irreversible acute medical condition, which leads to the necrosis of heart muscles secondary to extended ischemia. Myocardial infarction occurs when a part of heart is deprived of oxygen, which is caused due to the blockage of one of the coronary arteries. Usually blockage is developed due to the buildup of atherosclerotic plaque on the walls of arteries. Continue reading →

OBJECTIVE: To determine the frequency of no reperfusion therapy, its reasons, hospital management and intermediate-term outcome s of ST- elevation my ocardial in farction patients . The retrospective ambi-directional observational study was conducted at Tabba Heart Institute, Karachi, and comprised record of ST-elevationmyocardial infarctionpatients without immediate reperfusion therapy with symptom onset time of 12 hours who presented between January 2013 and December 2017. Prospective follow-up of all patients was performed till June 2018. Continue reading →

Zion Market Research added a new report on Myocardial Infarction Treatment Market Size & Share Research Report, 2018-2024" in its database. The Myocardial Infarction Treatment Market report analysis includes sales & revenue, industry size & Share, analysis by value & volume, Trends, growth prospects & major companies. Continue reading →

PHILADELPHIA Even the sickest of patients with acute heart failure (HF) can be safely started on sacubitril/valsartan (Entresto, Novartis) in the intensive-care unit (ICU) as part of their careful transition from IV vasodilators and inotropes to oral therapy, suggests an early experience of fewer than 2 dozen cases. Continue reading →

INTRODUCTION: ST-segment elevationmyocardial infarction(STEMI) is a time-sensitive entity that has been shown to benefit from prehospital diagnosis by electrocardiogram (ECG). Current computer algorithms with binary decision making are not accurate enough to be relied on for cardiac catheterization lab (CCL) activation. Continue reading →

PARIS Obese patients with type 2 diabetes who underwent bariatric (metabolic) surgery were less likely than similar patients who received medical treatment to experience one of six major adverse cardiovascular events (MACE), findings of a new observational study show. Compared with obese patients with type 2 diabetes who received medical treatment, those who underwent bariatric surgery were 39% less likely to die from any cause or to develop heart failure, coronary artery events, cerebrovascular events, atrial fibrillation, or nephropathy in the following 8 years, Ali Aminian MD, bariatric surgeon at the Cleveland Clinic, in Ohio, reported here in a late-breaking science session of the European Society of Cardiology (ESC) Congress 2019, World Congress of Cardiology. The study was simultaneously published online September 2 in JAMA Continue reading →